Quick answer: A 2026 report described oral NMN use in dogs with elevated NT-proBNP and reported reductions in that biomarker in some dogs. The study is interesting but should not be interpreted as proof that NMN treats heart disease or as a dosing guide for pet owners. Further controlled clinical studies are needed.
What was studied?
The report evaluated dogs with elevated NT-proBNP, a biomarker used in veterinary cardiology. Dogs received oral NMN at weight-adjusted amounts, and researchers followed NT-proBNP and other clinical information.
What did the authors report?
The authors reported larger improvements in dogs without major structural abnormalities or with mild-to-moderate biomarker elevation. Dogs with severe disease or more complex conditions had more limited responses and required conventional treatment.
Why this is not a treatment recommendation
- The publication was not a large randomized placebo-controlled trial.
- A biomarker change is not the same as proving improved survival or clinical outcome.
- The studied dogs were veterinary patients, not healthy pets taking a retail wellness chew.
- The authors themselves called for further controlled studies.
Do not copy the study dose
A dose used in a veterinary study should not be converted into a home supplement plan without veterinary oversight. Product formulation, health status, kidney function, heart disease and concurrent medications can all change the risk-benefit discussion.
How does this fit with older canine NAD-related research?
Other dog research includes a randomized trial of a combined senolytic and NAD+ precursor in senior dogs with cognitive impairment. Because that product combined active components, its effects cannot be assigned to NMN alone.
What should shoppers verify on a NAD-related product?
- The exact compound: NAD+, NMN, NR, niacinamide or something else.
- Amount per labeled serving.
- Species directions.
- Other active ingredients.
- Storage and cautions.
- Whether claims match actual canine evidence.
Related PetVibess guides
Sources
- 2026 canine NMN and NT-proBNP report
- Randomized controlled canine NAD+ precursor combination trial
- NMN subacute toxicity study including beagle dogs
Written by the PetVibess Editorial Team. General educational information only; not veterinary diagnosis, cardiology advice, or dosing guidance. Updated October 3, 2026.